home / stock / akba / akba articles
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (C...
Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results. RH posted weaker-than-expecte...
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Cintas Corporation (NASDAQ: CTAS) rose sharply ...
HC Wainwright has upgraded Akebia Therapeutics Inc (NASDAQ: AKBA) from Neutral to Buy rating. Analysts Ed Arce ...
Covered a research piece on Akebia Therapeutics, a biopharmaceutical developing cutting-edge therapies for the treatment of patients with kidney diseases.
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference PR Newswire CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purp...
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer PR Newswire CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with t...
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference PR Newswire CAMBRIDGE, Mass. , May 23, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better t...